Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Orlando Landrum

Interventional Pain Medicine Elkhart, IN Medical Doctor

NPI 1932159910 CMS profile 1243607

242 Waterfall Dr, Suite B, Elkhart, IN 46516

Open in the dashboard

General payments

$34,238

114 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Orlando Landrum of Elkhart, IN is reported in the CMS Open Payments database as having received $34,238 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,020 6
2024 General $1,355 19
2023 General $963 9
2022 General $16,044 34
2021 General $9,612 30
2020 General $110 7
2019 General $134 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Orlando Landrum
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Orlando Landrum were reported at $6,020. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Orlando Landrum Interventional Pain Medicine median Middle half National median
2019 $134 $684 $216–$2,079 $163
2020 $110 $382 $122–$1,109 $114
2021 $9,612 $552 $167–$1,554 $132
2022 $16,044 $605 $187–$1,924 $149
2023 $963 $671 $195–$1,915 $160
2024 $1,355 $684 $206–$1,837 $164
2025 $6,020 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GRT US Holding, Inc. $17,662 20 payments
  2. Neuronetics, Inc. $11,897 17 payments
  3. AcelRx Pharmaceuticals, Inc. $1,619 2 payments
  4. Abbott Laboratories $1,117 15 payments
  5. Genesys Orthopedics Systems, L.L.C. $759 4 payments
  6. Boston Scientific Corporation $323 9 payments
  7. Nalu Medical, Inc. $211 17 payments
  8. Nevro Corp. $119 4 payments
  9. Kerecis Limited $100 1 payment
  10. Collegium Pharmaceutical, Inc. $64 4 payments
  11. Other $368 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $17,300 6 payments
  2. Debt forgiveness $6,122 6 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $4,800 1 payment
  4. Food and Beverage $3,709 95 payments
  5. Travel and Lodging $2,142 4 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150 1 payment
  7. Gift $15 1 payment
Products named General payments · program years 2019–2025
  1. Qutenza $17,662 20 payments
  2. Neurostar TMS Therapy System Neurostar Tms Therapy System $6,642 12 payments
  3. NEUROSTAR TMS THERAPY SYSTEM Neurostar Tms Therapy System $5,255 5 payments
  4. DSUVIA $1,619 2 payments
  5. Sacroiliac Joint Fusion System $759 4 payments
  6. Proclaim IPG $510 5 payments
  7. PROCLAIM Neuromodulation $369 5 payments
  8. Nalu Neurostimulation System $211 17 payments
  9. WaveWriter Alpha Prime 16 $165 1 payment
  10. PROCLAIM Neuromodulation $140 1 payment
  11. Other $1,276 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Interventional Pain Management: 1,220

Drug cost

$238

Median for Interventional Pain Management: $39,344

Branded share of claims

0%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 14 $238

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$12,149

Medicare's payments for the services billed

Medicare patients

116

Average age 71

Services billed

123

64 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 41%
Ischemic heart disease 31%
Chronic kidney disease 31%
Heart failure 26%
Cancer 25%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record